biostudies-literatureUnknown8(4)Ramaswamy ANag Foundation Grant to the instituteTMC Research Administrative Council (TRAC) Tata Memorial Centre<h4>Background</h4>We evaluated whether the addition of docetaxel (D) to a combination comprising 5-fluorouracil/leucovorin (5-FU/LV) or capecitabine (C) plus oxaliplatin (O) (DOF/DOX) improved overall survival (OS) compared with 6 months of 5-fluorouracil (5-FU) or capecitabine in combination with oxaliplatin (FOLFOX/CAPOX) alone in advanced HER2-negative gastroesophageal junction and gastric adenocarcinomas (G/GEJ).<h4>Methods</h4>This study was an investigator-initiated, open-label, multi-institutional, randomized phase III trial in adult patients with HER2-negative advanced G/GEJs. The primary endpoint of the study was a comparison of median OS by Kaplan-Meier method. Next-generation sequencing was performed on tissue.<h4>Results</h4>Of the 324 patients randomly assigned between July 2JNCI cancer spectrumpkae054https://www.ebi.ac.uk/biostudies/studies/S-EPMC11316615biostudies-literatureDocetaxel-oxaliplatin-capecitabine/5-fluorouracil (DOX/F) followed by docetaxel versus oxaliplatin-capecitabine/5-fluorouracil (CAPOX/FOLFOX) in HER2-negative advanced gastric cancers.PMC11316615Singh SNAnkathi SKDhal IGupta ADesai VNoronha VPatil RRamaswamy APatel SMenon NKapoor APrabhash KSrinivas SJadhav PMishra BKDubashi BShetty OPal VNashikkar CParulekar MBhargava PSyed NSingh AGanesan PJoshi ASuganiya RKayal SAnanthakrishnan RKaushal RKSansar BKannan SChaugule DPatil VMMandavkar SShah ASrinivasan NDKapu VVinayak KRSamaddar DKaaviya DOstwal VfalseDocetaxel-oxaliplatin-capecitabine/5-fluorouracil (DOX/F) followed by docetaxel versus oxaliplatin-capecitabine/5-fluorouracil (CAPOX/FOLFOX) in HER2-negative advanced gastric cancers.<h4>Background</h4>We evaluated whether the addition of docetaxel (D) to a combination comprising 5-fluorouracil/leucovorin (5-FU/LV) or capecitabine (C) plus oxaliplatin (O) (DOF/DOX) improved overall survival (OS) compared with 6 months of 5-fluorouracil (5-FU) or capecitabine in combination with oxaliplatin (FOLFOX/CAPOX) alone in advanced HER2-negative gastroesophageal junction and gastric adenocarcinomas (G/GEJ).<h4>Methods</h4>This study was an investigator-initiated, open-label, multi-institutional, randomized phase III trial in adult patients with HER2-negative advanced G/GEJs. The primary endpoint of the study was a comparison of median OS by Kaplan-Meier method. Next-generation sequencing was performed on tissue.<h4>Results</h4>Of the 324 patients randomly assigned between July 22024-01-01T00:00:00Z2024 Jul2025-04-22T14:46:51.404Z2025-04-06T01:11:07.117ZS-EPMC113166153906703710.1093/jncics/pkae054